Drug Profile
KI 0805
Alternative Names: KI0805Latest Information Update: 08 May 2015
Price :
$50
*
At a glance
- Originator Kuhnil Pharmaceutical Company
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 01 Feb 2011 Phase-III clinical trials in Obesity in South Korea (unspecified route)